Cardiogen appoints Scientific Advisory Board

Munich, August 25, 2025 - Cardiogen GmbH today announced that it has appointed its newly formed Scientific Advisory Board, reflecting the company's entering of the pre- and clinical program.

This newly formed Scientific Advisory Board represents a first selection of world class key opinion leaders and clinicians, who either already contributed or are now supporting Cardiogen in the  scientific and clinical development of its regenerative gene therapy in cardiovascular diseases.

The Chairman of the Steering Committee is Andrew Coats, PhD, MD, President of Heart Research Institute, University of Sydney, Australia and former President of the Heart Failure Association.

He is supported by Jozef Bartunek, PhD, MD, Interventional Cardiologist and Associate Director at Cardiovascular Center, Aalst, OLV Hospital, Belgium.

Dr. Roman Schenk, Member of the Cardiogen Board and Co-Founder commented: “We are extremely proud that these key opinion leaders have joined our Scientific Advisory Board Committee and will early on contribute with their excellent and long lasting scientific and clinical experience to our development program in the cardiovascular area.” 

About Cardiogen

Cardiogen’s non-invasive regenerative approach can potentially play a significant role in improving the survival rate and quality of life for patients who experience a heart attack, as well as in various other cardiovascular diseases. 

For more information, visit: https://www.cardiogentx.com/ or contact info@cardiogentx.com